Related references
Note: Only part of the references are listed.3-Bromopyruvate as a potent covalently reversible inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1)
Peng-Wei Kang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Identification of Cisplatin and Palladium(II) Complexes as Potent Metallo-β-lactamase Inhibitors for Targeting Carbapenem-Resistant Enterobacteriaceae
Chen Cheng et al.
ACS INFECTIOUS DISEASES (2020)
Hydroxamic acid with benzenesulfonamide: An effective scaffold for the development of broad-spectrum metallo-β-lactamase inhibitors
Jia-Qi Li et al.
BIOORGANIC CHEMISTRY (2020)
Disulfiram as a potent metallo-β-lactamase inhibitor with dual functional mechanisms
Cheng Chen et al.
CHEMICAL COMMUNICATIONS (2020)
meta-Substituted benzenesulfonamide: a potent scaffold for the development of metallo-β-lactamase ImiS inhibitors
Ya Liu et al.
RSC MEDICINAL CHEMISTRY (2020)
Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development
Petra Heffeter et al.
ANTIOXIDANTS & REDOX SIGNALING (2019)
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2019)
H2depda: An acyclic adjuvant potentiates meropenem activity in vitro against metallo-β-lactamase-producing enterobacterales
Xiu-Fang Shi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Novel thiosemicarbazone derivatives containing indole fragment as potent and selective anticancer agent
Zhangxu He et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials
Petra Reimerova et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2019)
A protein structure-guided covalent scaffold selectively targets the B1 and B2 subclass metallo-β-lactamases
Cheng Chen et al.
CHEMICAL COMMUNICATIONS (2018)
Rhodanine as a Potent Scaffold for the Development of Broad Spectrum Metallo-β-lactamase inhibitors
Yang Xiang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Bioorthogonal Profiling of a Cancer Cell Proteome Identifies a Large Set of 3-Bromopyruvate Targets beyond Glycolysis
Narek Darabedian et al.
ACS CHEMICAL BIOLOGY (2018)
COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo (vol 7, pg 41363, 2016)
Kowthar Y. Salim et al.
ONCOTARGET (2017)
Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam
Adam B. Shapiro
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Design, synthesis and biological evaluation of thiosemicarbazones, hydrazinobenzothiazoles and arylhydrazones as anticancer agents with a potential to overcome multidrug resistance
Veronika F. S. Pape et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Inhibition of Bacillus anthracis metallo-β-lactamase by compounds with hydroxamic acid functionality
Sung-Kun Kim et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2016)
The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms
Zhu-Ling Guo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Cross-class metallo-β-lactamase inhibition by bisthiazolidines reveals multiple binding modes
Philip Hinchliffe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria
Franca-M Klingler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Biochemical, Mechanistic, and Spectroscopic Characterization of Metallo-β-lactamase VIM-2
Mahesh Aitha et al.
BIOCHEMISTRY (2014)
Aspergillomarasmine A overcomes metallo-β-lactamase antibiotic resistance
Andrew M. King et al.
NATURE (2014)
Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition
Juergen Brem et al.
NATURE CHEMISTRY (2014)
Mechanistic and Spectroscopic Studies of Metallo-β-lactamase NDM-1
Hao Yang et al.
BIOCHEMISTRY (2012)
Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo
David B. Lovejoy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Bioactivation of antituberculosis thioamide and thiourea prodrugs by bacterial and mammalian flavin monooxygenases
Clinton R. Nishida et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2011)
Updated Functional Classification of beta-Lactamases
Karen Bush et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
Steven Attia et al.
INVESTIGATIONAL NEW DRUGS (2008)
Role of the Zn1 and Zn2 sites in Metallo-β-lactamase L1
Zhenxin Hu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity
Des R. Richardson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Metallo-β-lactamases:: Novel weaponry for antibiotic resistance in bacteria
Michael W. Crowder et al.
ACCOUNTS OF CHEMICAL RESEARCH (2006)
A new approach to the inhibition of metallo-beta-lactamases
J Spencer et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Bacterial resistance to β-lactam antibiotics:: Compelling opportunism, compelling opportunity
JF Fisher et al.
CHEMICAL REVIEWS (2005)
Over-expression, purification, and characterization of metallo-β-lactamase ImiS from Aeromonas veronii bv. sobria
PA Crawford et al.
PROTEIN EXPRESSION AND PURIFICATION (2004)